SCHEDULE: Vanguard Discloses 5.19% Stake in Korro Bio Inc

The Vanguard Group reported a 5.19% beneficial ownership stake in Korro Bio Inc, holding 489,639 shares of common stock as of December 31, 2025.

Summary

• The Vanguard Group reported beneficial ownership of 489,639 shares of Korro Bio Inc common stock.
• This represents 5.19% of the class of securities.
• Vanguard holds shared voting power over 43,589 shares and shared dispositive power over 489,639 shares.
• An internal realignment occurred at The Vanguard Group on January 12, 2026, where it ceased performing portfolio management services and proxy voting, with subsidiaries expected to report beneficial ownership separately.
• The holdings reported include securities in the form of rights.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it confirms a significant institutional presence in Korro Bio Inc, which can provide stability, though it's primarily a passive investment.

Positives

• A major institutional investor, The Vanguard Group, holds a significant 5.19% stake in Korro Bio Inc, indicating institutional presence.
• The acquisition of shares was in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Negatives

• The Vanguard Group underwent an internal realignment on January 12, 2026, ceasing portfolio management services and proxy voting, which means future beneficial ownership reports may be disaggregated from the parent entity.

Industry Context

StockSavvy.ai notes that the disclosure of a significant stake by a major passive investment manager like The Vanguard Group is a routine event for publicly traded companies. It reflects Korro Bio Inc's inclusion in various Vanguard index funds and ETFs, rather than an active investment decision based on specific company performance or strategy.

Comparison to Industry Standards

• The 5.19% stake held by Vanguard is a typical level for a large institutional investor tracking broad market indices, comparable to holdings seen in other biotechnology companies within similar market capitalizations that are part of major indices.
• For example, similar passive stakes are often observed in companies like Moderna (MRNA) or BioNTech (BNTX) by large index funds, reflecting their market presence rather than a unique investment thesis.

Management Changes

Stakeholder Impact

• Shareholders: The presence of a large institutional investor like Vanguard can lend credibility and liquidity to the stock.
• Management: No direct impact on Korro Bio Inc's management or operations from this passive ownership.

Next Steps

• The Vanguard Group anticipates that certain subsidiaries or business divisions will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on SEC Release No. 34-39538.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of passive institutional ownership by The Vanguard Group. It does not provide new fundamental information about Korro Bio Inc's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The stake is consistent with a large index fund's holdings, suggesting a 'hold' recommendation as it neither presents new positive catalysts nor significant negative concerns for the issuer.

Keywords

Korro Bio Inc, Vanguard Group, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, 500946108, Schedule 13G